Compass Therapeutics, Inc. (NASDAQ:CMPX) Director Buys $76,497.78 in Stock

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) Director Carl Gordon acquired 30,722 shares of the firm’s stock in a transaction dated Friday, May 13th. The shares were purchased at an average price of $2.49 per share, for a total transaction of $76,497.78. Following the completion of the transaction, the director now directly owns 14,817,994 shares in the company, valued at $36,896,805.06. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of NASDAQ:CMPX traded down $0.01 on Wednesday, reaching $2.44. The company’s stock had a trading volume of 342 shares, compared to its average volume of 267,686. Compass Therapeutics, Inc. has a 52-week low of $1.25 and a 52-week high of $5.92. The company has a 50-day simple moving average of $1.58 and a 200 day simple moving average of $2.09.

Compass Therapeutics (NASDAQ:CMPX – Get Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.07. On average, analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

CMPX has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, April 4th. B. Riley began coverage on shares of Compass Therapeutics in a report on Tuesday, January 18th. They issued a “buy” rating and a $10.00 price target on the stock. HC Wainwright began coverage on shares of Compass Therapeutics in a report on Friday, January 21st. They issued a “buy” rating and a $11.00 price target on the stock. Finally, LADENBURG THALM/SH SH began coverage on shares of Compass Therapeutics in a report on Tuesday, March 15th. They issued a “buy” rating and a $7.00 price target on the stock. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $9.14.

A number of hedge funds have recently made changes to their positions in the stock. Difesa Capital Management LP acquired a new stake in Compass Therapeutics in the fourth quarter valued at approximately $33,000. Monashee Investment Management LLC acquired a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $6,340,000. Qube Research & Technologies Ltd acquired a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $92,000. New Capital Management LP acquired a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $77,000. Finally, CM Management LLC acquired a new stake in shares of Compass Therapeutics in the first quarter worth approximately $411,000. Institutional investors own 66.04% of the company’s stock.

About Compass Therapeutics (Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area.

Featured Stories